Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.52 |
| ▸ | SLC6A9 | P48067 | 4/20 | 0.47 |
| ▸ | GPX4 | P36969 | 3/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.46 |
| ▸ | HTR1A | P08908 | 2/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.46 |
| ▸ | DRD1 | P21728 | 2/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | BCL2 | P10415 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1782142 | 0.98 | CYP2D6 (0.50) | CYP2D6CYP19A1SLC6A9GPX4CHRM2 | |
| Bromide SCHEMBL1782497 | 0.98 | CYP2D6 (0.50) | CYP2D6CYP19A1SLC6A9GPX4CHRM2 | |
| SCHEMBL1779185 | 0.93 | CYP2D6 (0.46) | CYP2D6CYP19A1SLC6A9GPX4CHRM2 | |
| SCHEMBL3298070 | 0.84 | MAPK1 (0.40) | CYP2D6CYP19A1SLC6A9GPX4CHRM2 | |
| SCHEMBL3301126 | 0.82 | OPRD1 (0.51) | CYP2D6SLC6A9GPX4CYP2C19OPRM1 | |
| SCHEMBL3301129 | 0.82 | OPRD1 (0.51) | CYP2D6SLC6A9GPX4CYP2C19OPRM1 | |
| SCHEMBL3298937 | 0.81 | OPRM1 (0.44) | CYP2D6CYP19A1SLC6A9CHRM2HTR1A | |
| SCHEMBL1500612 | 0.80 | MGLL (0.43) | CYP2D6CYP19A1GPX4CHRM2HTR1A | |
| SCHEMBL1500614 | 0.80 | MGLL (0.43) | CYP2D6CYP19A1GPX4CHRM2HTR1A | |
| SCHEMBL7275198 | 0.80 | ACHE (0.46) | CYP2D6CYP19A1CHRM2HTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2229355-B1 | METHOD FOR PREPARING AZETIDINE DERIVATIVES | SANOFI SA (FR) | 2012-09-19 | — | — | EP | claimed |
| US-8207355-B2 | Method for preparing azetidine derivatives | SANOFI-AVENTIS (FR) | 2012-06-26 | — | — | US | claimed |
| US-20110118481-A1 | METHOD FOR PREPARING AZETIDINE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-05-19 | — | — | US | claimed |
| EP-2229355-A1 | METHOD FOR PREPARING AZETIDINE DERIVATIVES | Sanofi-Aventis (FR) | 2010-09-22 | — | — | EP | claimed |
| WO-2009103883-A1 | METHOD FOR PREPARING AZETIDINE DERIVATIVES | SANOFI-AVENTIS (FR) | 2009-08-27 | — | — | WO | claimed |
| EP-1805167-A2 | NOVEL PRODUCT, METHOD AND INTERMEDIATES FOR THE PREPARATION OF AZETIDINE DERIVATIVES | Aventis Pharma S.A. (FR) | 2007-07-11 | — | — | EP | claimed |
| WO-2006040465-A2 | NOVEL PRODUCT, METHOD AND INTERMEDIATES FOR THE PREPARATION OF AZETIDINE DERIVATIVES | AVENTIS PHARMA S.A. (FR) | 2006-04-20 | — | — | WO | claimed |
| US-8334282-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes | JENRIN DISCOVERY, INC. (US) | 2012-12-18 | — | — | US | disclosed |
| US-8334282-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes | JENRIN DISCOVERY, INC. (US) | 2012-12-18 | — | — | US | disclosed |
| US-8334282-B2 | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes | JENRIN DISCOVERY, INC. (US) | 2012-12-18 | — | — | US | disclosed |
| EP-2229355-B1 | METHOD FOR PREPARING AZETIDINE DERIVATIVES | SANOFI SA (FR) | 2012-09-19 | — | — | EP | disclosed |
| US-8207355-B2 | Method for preparing azetidine derivatives | SANOFI-AVENTIS (FR) | 2012-06-26 | — | — | US | disclosed |
| US-8207355-B2 | Method for preparing azetidine derivatives | SANOFI-AVENTIS (FR) | 2012-06-26 | — | — | US | disclosed |
| US-20020019383-A1 | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation | AVENTIS PHARMA S.A. (FR) | 2002-02-14 | — | — | US | disclosed |
| US-20010027193-A1 | Azetidine derivatives, their preparation and pharmaceutical compositions containing them | AVENTIS PHARMA S.A. (FR) | 2001-10-04 | — | — | US | disclosed |
| WO-2001064633-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING 3-AMINO-AZETIDINE DERIVATIVES, NOVEL DERIVATIVES AND PREPARATION THEREOF | AVENTIS PHARMA S.A. (FR) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001064632-A1 | AZETIDINE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA S.A. (FR) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001064634-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING AZETIDINE DERIVATIVES, NOVEL AZETIDINE DERIVATIVES AND PREPARATION THEREOF | AVENTIS PHARMA S.A. (FR) | 2001-09-07 | — | — | WO | disclosed |
| EP-1112251-A1 | AZETIDINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | Aventis Pharma S.A. (FR) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000015609-A1 | AZETIDINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027193-A1 | Azetidine derivatives, their preparation and pharmaceutical compositions containing them | ALK, CYP2C9, CBR1 | CYP2D6 7/4885CYP19A1 617/4885SLC6A9 1600/4885 |
| US-20020019383-A1 | Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation | HRH2, ALK, HRH1 | CYP2D6 4/4885CYP19A1 720/4885SLC6A9 1475/4885 |
| US-20110118481-A1 | METHOD FOR PREPARING AZETIDINE DERIVATIVES | QDPR, AZI2, NISCH | CYP2D6 183/4885CYP19A1 740/4885SLC6A9 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.